What's next for cancer vaccines.
| Autor: | Adamik J; Parker Institute for Cancer Immunotherapy, University of California, San Francisco, Suite D3500, 1 Letterman Drive, San Francisco, CA 94129, USA., Butterfield LH; Parker Institute for Cancer Immunotherapy, University of California, San Francisco, Suite D3500, 1 Letterman Drive, San Francisco, CA 94129, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Science translational medicine [Sci Transl Med] 2022 Nov 09; Vol. 14 (670), pp. eabo4632. Date of Electronic Publication: 2022 Nov 09. |
| DOI: | 10.1126/scitranslmed.abo4632 |
| Abstrakt: | Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|